GLRA
VRTX icon

Gerald L. Ray & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Gerald L. Ray & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$5.42M Sell
35,670
-1,400
-4% -$211K 0.68% 35
2017
Q2 		$4.78M Sell
37,070
-300
-0.8% -$36.1K 0.62% 39
2017
Q1 		$4.09M Sell
37,370
-100
-0.3% -$8.8K 0.56% 46
2016
Q4 		$2.76M Sell
37,470
-400
-1% -$32.5K 0.4% 64
2016
Q3 		$3.3M Sell
37,870
-1,100
-3% -$104K 0.5% 52
2016
Q2 		$3.35M Hold
38,970
– – 0.54% 50
2016
Q1 		$3.1M Sell
38,970
-300
-0.8% -$27.1K 0.5% 52
2015
Q4 		$4.94M Hold
39,270
– – 0.78% 33
2015
Q3 		$4.09M Sell
39,270
-100
-0.3% -$12.8K 0.68% 40
2015
Q2 		$4.86M Sell
39,370
-760
-2% -$95.8K 0.74% 36
2015
Q1 		$4.73M Sell
40,130
-4,100
-9% -$491K 0.71% 37
2014
Q4 		$5.25M Hold
44,230
– – 0.81% 34
2014
Q3 		$4.97M Sell
44,230
-1,370
-3% -$130K 0.81% 36
2014
Q2 		$4.32M Sell
45,600
-350
-0.8% -$24.5K 0.74% 40
2014
Q1 		$3.25M Buy
45,950
+60
+0.1% +$4.75K 0.59% 44
2013
Q4 		$3.41M Sell
45,890
-880
-2% -$61.3K 0.64% 43
2013
Q3 		$3.55M Sell
46,770
-300
-0.6% -$23.9K 0.73% 40
2013
Q2 		$3.77M Buy
+47,070
New +$3.47M 0.84% 36

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Gerald L. Ray & Associates's VRTX Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q3 2017, selling an estimated $211K and leaving 35,670 shares worth $5.42M. The position accounts for 0.68% of the portfolio, ranked #35.

Gerald L. Ray & Associates first reported a position in VRTX in Q2 2013 and has held it in 18 quarters since. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • Gerald L. Ray & Associates held 35,670 shares of Vertex Pharmaceuticals worth $5.42M as of Q3 2017.
  • Gerald L. Ray & Associates sold 1,400 Vertex Pharmaceuticals shares in Q3 2017, an estimated $211K.
  • Vertex Pharmaceuticals made up 0.68% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #35 holding.
  • Gerald L. Ray & Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.